Full Press Release Details
SAN DIEGO , Aug. 22, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Anne Wojcicki , co-founder and CEO of personal genomics company 23andMe, at its inaugural Illumina Genomics Forum (IGF) on October 1 . In a spotlight session titled "Disruption Ahead," Wojcicki will speak with biotechnology journalist Luke Timmerman about putting the consumer at the center of health care, drawing from her personal experience disrupting the health care status quo, and improving patient lives through genomics innovation.
During the conversation, Wojcicki will discuss how a consumer-first approach to health care continues to guide her as she leads 23andMe into its next growth phase. Late last year, 23andMe acquired Lemonaid Health, a telemedicine platform and digital pharmacy, to advance its vision of individualized primary care and empower consumers to live healthier lives. Wojcicki will also share her vision for industry standards to guide data privacy and sharing, as well as her views on key actions needed to improve and accelerate drug discovery.
Illumina previously announced that former US President Barack Obama will headline the inaugural forum in a fireside chat on the evening of Wednesday, September 28 . Twelve years after the passage of the Affordable Care Act, Obama will discuss the continued need for equity, accessibility, and smarter health care to improve the human condition. Then, on September 30 , Bill Gates , co-chair of the Bill & Melinda Gates Foundation, will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health.
Other IGF key themes include:
IGF will take place in San Diego from September 28 through October 1 . For more information and to register for the conference, go to illuminagenomicsforum.com .
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .
Investors: Salli Schwartz 858-291-6421 [email protected]
Media: Adi Raval 202-629-8172 [email protected]
SOURCE Illumina, Inc.